(For other news from the Reuters India Investment Summit, click
BANGALORE Nov 23 Biocon Ltd, India's
largest listed biotechnology company, expects to find a
deep-pocketed global partner for its experimental oral insulin
pill by end-March, its top executive said on
"We are in advanced discussions with potential
partners," Biocon's Managing Director Kiran Mazumdar-Shaw told
the Reuters India Investment Summit in Bangalore.
In January, Biocon had said it was looking for a partner
after its oral insulin, IN-105, failed to meet the main goal of
an Indian late-stage trial in patients with type-2 diabetes.
Mazumdar-Shaw, however, declined to name any potential
She also said the planned IPO of its contract research
organisation, Syngene, was on track.
(For summit blog: blogs.reuters.com/summits/)
(For more on the Reuters India Investment Summit, see
(Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in
Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)